Evidence map›Paper›PMID 29116244›Full record

ArticleSpinal cord2018

Delivery of neostigmine and glycopyrrolate by iontophoresis: a nonrandomized study in individuals with spinal cord injury.

Mark A Korsten, Brian L Lyons, Miroslav Radulovic, Tradd M Cummings, Gautam Sikka, Kamaldeep Singh, Joshua C Hobson, Anton Sabiev, Ann M Spungen, William A Bauman

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Spinal cord, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04027972 (Pharmacokinetics of Neostigmine and Glycopyrrolate After Intravenous and Transcutaneous Administration by Iontophoresis), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04027972 early_phase1completednot on this mapstarted 2020, after this paper: background citation

Pharmacokinetics of Neostigmine and Glycopyrrolate After Intravenous and Transcutaneous Administration by Iontophoresis

TypeinterventionalSponsorJames J. Peters Veterans Affairs Medical CenterRan2020 to 2022Enrolled13ConditionsSpinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic BowelArmsCombination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Rethinking asthma therapy, part 2: transdermal strategies for adjunct asthma and allergy treatments.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026
    Review
  2. Recent Developments in On-Demand Voiding Therapies.The Journal of pharmacology and experimental therapeutics · 2024
    Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Mark A KorstenNational Center for the Medical Consequences of Spinal Cord Injury, Bronx, NY, USA. mark.korsten@va.gov.
Brian L LyonsNational Center for the Medical Consequences of Spinal Cord Injury, Bronx, NY, USA.
Miroslav RadulovicNational Center for the Medical Consequences of Spinal Cord Injury, Bronx, NY, USA.
Tradd M CummingsNational Center for the Medical Consequences of Spinal Cord Injury, Bronx, NY, USA.
Gautam SikkaMedical Service, James J. Peters VA Medical Center, Bronx, NY, USA.
Kamaldeep SinghNational Center for the Medical Consequences of Spinal Cord Injury, Bronx, NY, USA.
Joshua C HobsonNational Center for the Medical Consequences of Spinal Cord Injury, Bronx, NY, USA.
Anton SabievNational Center for the Medical Consequences of Spinal Cord Injury, Bronx, NY, USA.
Ann M SpungenNational Center for the Medical Consequences of Spinal Cord Injury, Bronx, NY, USA.ORCID http://orcid.org/0000-0003-2242-2119
William A BaumanNational Center for the Medical Consequences of Spinal Cord Injury, Bronx, NY, USA.
James J. Peters VA Medical Center · USIcahn School of Medicine at Mount Sinai · US

Funding

RRD VA B9212-C
6 · The paper itself

Abstract

STUDY

designPhase I Clinical Trial.

objectivesIn this proof-of-principle study, the effectiveness and safety of transdermal administration of neostigmine/glycopyrrolate to elicit a bowel movement was compared to intravenous administration in patients with spinal cord injury.

settingJames J. Peters Veterans Affairs Medical Center (Bronx, NY).

methodsIndividuals were screened for responsiveness (Physical Response) to intravenous neostigmine (0.03 mg/kg)/glycopyrrolate (0.006 mg/kg). Intravenous neostigmine/glycopyrrolate responders (Therapeutic Response) were administered low-dose transdermal neostigmine/glycopyrrolate [(0.05 mg/kg)/(0.01 mg/kg)] by iontophoresis. Non-responders to low-dose transdermal neostigmine/glycopyrrolate were administered high-dose transdermal neostigmine/glycopyrrolate [(0.07 mg/kg)/(0.014 mg/kg)] by iontophoresis. Bowel movement, bowel evacuation time, and cholinergic side effects were recorded. Visits were separated by 2 to 14 days.

resultsEighteen of 25 individuals (72.0%) had a bowel movement (20 ± 22 min) after intravenous neostigmine/glycopyrrolate. Of these 18 individuals, 5 individuals experienced a bowel movement with low-dose transdermal neostigmine/glycopyrrolate. Another five individuals had a bowel movement after high-dose transdermal neostigmine/glycopyrrolate administration. Fewer side effects were observed in individuals who received neostigmine/glycopyrrolate transdermally compared to those who were administered intravenous neostigmine/glycopyrrolate.

conclusionsTransdermal administration of neostigmine/glycopyrrolate by iontophoresis appears to be a practical, safe, and effective approach to induce bowel evacuation in individuals with spinal cord injury.

Indexed as

Administration, IntravenousAdolescentAdultAgedCholinesterase InhibitorsDose-Response Relationship, DrugDrug CombinationsFemaleGlycopyrrolateHumansIontophoresisMaleMiddle AgedMuscarinic AntagonistsNeostigmineNeurogenic BowelCholinesterase InhibitorsDrug CombinationsGlycopyrrolateMuscarinic AntagonistsNeostigmine

Identifiers

PMID29116244
PMCPMC5839930
OpenAlexW2766863543

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.